Allergy Therapeutics plc (AIM: AGY) has pioneered an ultra-short course allergy treatment (typically acute hayfever), Pollinex Quattro, which last year generated revenues in excess of £43m in Europe.
The ability to deliver a disease-modifying outcome as opposed to simply symptomatic relief, with short/ultrashort course treatments significantly differentiates Pollinex Quattro from its competitors.
AGY has established a significant market share in the European market, achieving double-digit compound annual revenue growth over the past 18 years. AGY is seeking to roll out Pollinex Quattro in the US, which has an estimated US$2bn market. To date 14 clinical trials have been completed, including phase I, II & III.
As at 30 June 2017 AGY had a cash balance of £22.1m.
To visit Allergy Therapeutics website, click here
Manuel Llobet (CEO)
Joined 2009. Previously CEO of International Operations of the Weinstein family’s group of companies.
Nick Wykeman (FD)
Ex Group Financial Controller of Skyepharma. Held same role at Quest International (part of ICI PLC)
Peter Jensen (NE Chairman)
21yrs with SmithKline Beecham. Previously NED of several listed businesses.
NED’s – Thomas Lander (25 yrs R&D in pharma), Stephen Smith (management accountant), Jeff Barton (VP licensing & acquisitions, Abbott)
“Novel Findings Further Highlight the Effectiveness of MCT as Alternative to Alum and its Potential Advantage in Allergy-Specific Immunotherapy” Allergy …
Allergy Thereapeutics plc (LON:AGY) this morning released their Interim Results for the 6 months ended 31st December 2017. A short …
Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for …
Allergy Therapeutics plc (AIM AGY) has signed a contract with the German based AGC Biologics to scale up manufacturing of …
Trial running ahead of schedule with data now due in early H2 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated …
Market share gains driving top line growth Strong cash position sustained by good performance. Allergy Therapeutics plc (AIM:AGY), the fully …
|Cost of Sales||(16,771)||(14,070)|
|Profit Before Tax/ (Loss)||(1,970)||(12,064)|
|Cash & cash equivalents||22,122||23,406|
ALK (OMX: ALKB)
Grass & ragweed allergy treatment
Stallergenes (EURO: STAGR)
Grass allergy treatment
Circassia (LSE: CIR)
Grass, cat & ragweed allergy treatment
Manuel Llobet – 0.55%
Stephen Smith – 0.13%
Peter Jensen – 0.03%
Nick Wykeman – 0.03%
Weinstein A ESQ – 40.54%
Southern Fox Investments Ltd – 21.45%
Odey Asset Management – 7.37%
Invesco AM – 5.75%
Blackrock – 3.20%
GlaxoSmithKlein PLC – 1.72%
“…the global vaccine market, in its entirety, has quadrupled in value since 2000 with the World Health Organisation estimating market growth to almost $100bn by 2025.” (Panmure Gordon note, June 2015)
“In the US, it is estimated over 80m people suffer from Allergic Rhinitis (AR), albeit with diagnosis rates which remain low at 31%.” (Panmure Gordon note, June 2015)
“Inside the £6bn race to find cures for food allergies”
“Children allergic to peanuts could soon be offered a short course of injections to cure them of the condition. AIM-listed Allergy Therapeutics has already tested the vaccine in the laboratory, and is poised to scale up production before applying for approval from regulators. It will then begin human trials.”
Daily Telegraph (July 2017): Hay fever vaccines spike Allergy Therapeutics shares
“A big bump in sales of vaccines for hay fever has sent shares in AIM-listed Allergy Therapeutics up 17% today.”
“Allergy Therapeutics (AGY) is attempting to revolutionise the immunotherapy market with the launch of its four-dose injection treatments and, eventually, its orally administered vaccines. ”
FinnCap (Initiation Jan 2017)
“(AGY) has a solid and profitable underlying European business with growing market share, strong growth (11% CAGR 2014-16) and the prospect of an approved and therefore fully marketable (rather than named patient) product in 2019… Coupled to this, we consider the US clinical programme for Pollinex Quattro …with further strategic assets that could exploit the untapped market for food allergies (e.g. peanut) and perennial rhinitis (e.g. house dust mite).